Regulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivator Gene CIITA
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Major histocompatibility complex (MHC) class II genes are expressed constitutively in only a few cell types, but they can be induced in the majority of them, in particular by interferon-gamma (IFN-gamma). The MHC class II transactivator gene CIITA is defective in a form of primary MHC class II deficiency. Here it is shown that CIITA expression is controlled and induced by IFN-gamma. A functional CIITA gene is necessary for class II induction, and transfection of CIITA is sufficient to activate expression of MHC class II genes in class II-negative cells in the absence of IFN-gamma. CIITA is therefore a general regulator of both inducible and constitutive MHC class II expression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The expression of PD-L1 and MHC II, which may cause exhaustion by binding to T-cell programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3), respectively, is regulated by tumor interferon (IFN) signaling.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [27]
Citations
Cites
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.
Gorman, C. M., Moffat, L. F., & Howard, B. H. (1982) · Molecular and Cellular Biology · doi:10.1128/mcb.2.9.1044 · Cited by 7,830
Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor
Schindler, C., Shuai, K., Prezioso, V. R., & Darnell, J. E. (1992) · Science · doi:10.1126/science.1496401 · Cited by 899
Steimle, V (1993) · Cell · doi:10.1016/0092-8674(93)90685-j · Cited by 864
A Single Phosphotyrosine Residue of Stat91 Required for Gene Activation by Interferon-γ
Shuai, K., Stark, G. R., Kerr, L. M., & Darnell, J. E. (1993) · Science · doi:10.1126/science.7690989 · Cited by 802
Activation of Transcription by IFN-γ: Tyrosine Phosphorylation of a 91-kD DNA Binding Protein
Shuai, K., Schindler, C., Prezioso, V. R., & Darnell, J. E. (1992) · Science · doi:10.1126/science.1281555 · Cited by 775
Collins, T., Korman, A. J., Wake, C. T., Boss, J. M., Kappes, D. J., Fiers, W., Ault, K. A., Gimbrone, M. A., Strominger, J. L., & Pober, J. S. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.15.4917 · Cited by 585
Sequences And Factors: A Guide To Mhc Class-Ii Transcription
Glimcher, L. (1992) · Annual Review of Immunology · doi:10.1146/annurev.immunol.10.1.13 · Cited by 534
Benoist, C., & Mathis, D. (1990) · Annual Review of Immunology · doi:10.1146/annurev.iy.08.040190.003341 · Cited by 457
Müller, M., Laxton, C., Briscoe, J., Schindler, C., Improta, T., Darnell, J. E., Stark, G. R., & Kerr, I. M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06106.x · Cited by 411
Detection of a novel human class II HLA antigen
Watson, A. J., DeMars, R., Trowbridge, I. S., & Bach, F. H. (1983) · Nature · doi:10.1038/304358a0 · Cited by 376
Cited by
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Antiviral Actions of Interferons
Samuel, C. E. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.778-809.2001 · Cited by 2,743
“Expression of CIITA and hence MHC class II is inducible by IFN- (59, 396).”
BackgroundStatins as a newly recognized type of immunomodulator.
Kwak, B., Mulhaupt, F., Myit, S., & Mach, F. (2000) · Nature Medicine · doi:10.1038/82219 · Cited by 1,383
“, CIITA is the general controller of MHC-II expression, and its own expression is tightly regulate”
BackgroundInterferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
The ins and outs of MHC class II-mediated antigen processing and presentation
Roche, P. A., & Furuta, K. (2015) · Nature reviews. Immunology · doi:10.1038/nri3818 · Cited by 1,207
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC
Besse, B., Charrier, M., Lapierre, V., Dansin, E., Lantz, O., Planchard, D., Le Chevalier, T., Livartoski, A., Barlesi, F., Laplanche, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1071008 · Cited by 749
“Previous studies have shown a link between MHC-II, IFN-g and BAG6, 20,21 the latter known to directly activate NK cells through engagement of the NKp30 receptor.”
MethodThe dual nature of type I and type II interferons
Lee, A. J., & Ashkar, A. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02061 · Cited by 690
“Further, Marshall et al. found that stimulation of NK cells with supernatants from CpG-stimulated pDCs in addition to IFN-α suppressed IFN-γ release from NK cells (60).”
BackgroundInfluentialMacrophages in intestinal homeostasis and inflammation
Bain, C. C., & Mowat, A. M. (2014) · Immunological Reviews · doi:10.1111/imr.12192 · Cited by 611
“IFNcR signaling is known to induce MHCII on m/ (104), but MHCII expression by intestinal m/ is normal in IFNcR-deficient mice (our unpublished observations).”
BackgroundInterferon-γ: teammate or opponent in the tumour microenvironment?
Gocher, A. M., Workman, C. J., & Vignali, D. A. A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00566-3 · Cited by 582
Riese, R. J., Wolf, P. R., Brömme, D., Natkin, L. R., Villadangos, J. A., Ploegh, H. L., & Chapman, H. A. (1996) · Immunity · doi:10.1016/s1074-7613(00)80249-6 · Cited by 535
The Bare Lymphocyte Syndrome and the Regulation of MHC Expression
Reith, W., & Mach, B. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.331 · Cited by 518
Muhlethaler-Mottet, A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2851 · Cited by 507
“It also represents (Steimle et al., 1994).”
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
Axelrod, M. L., Cook, R. S., Johnson, D. B., & Balko, J. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3200 · Cited by 490
“Importantly, CIITA is essential for MHC-II induction by IFNg (31).”
BackgroundREGULATION OF MHC CLASS II GENES: Lessons from a Disease
Mach, B., Steimle, V., Martinez-Soria, E., & Reith, W. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.301 · Cited by 486
Regulation of MHC class II gene expression by the class II transactivator
Reith, W., LeibundGut-Landmann, S., & Waldburger, J.-M. (2005) · Nature Reviews Immunology · doi:10.1038/nri1708 · Cited by 462
NLR family member NLRC5 is a transcriptional regulator of MHC class I genes
Meissner, T. B., Li, A., Biswas, A., Lee, K.-H., Liu, Y.-J., Bayir, E., Iliopoulos, D., van den Elsen, P. J., & Kobayashi, K. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008684107 · Cited by 447
“Discussion Since the complementation cloning of CIITA fromMHC class IIdeficient patients in 1993, CIITA has been often referred to as a master regulator of MHC class II expression, because CIITA is required for both constitutive and IFN-γ–inducible transcription of MHC class II genes (15, 20, 32).”
BackgroundInfluentialRegulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors
Harding, C. V., & Boom, W. H. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2321 · Cited by 435
Interferon-γ: Biology and Role in Pathogenesis
Billiau, A. (1996) · Advances in Immunology · doi:10.1016/s0065-2776(08)60428-9 · Cited by 433
Cellular backpacks for macrophage immunotherapy
Shields, C. W., Evans, M. A., Wang, L. L.-W., Baugh, N., Iyer, S., Wu, D., Zhao, Z., Pusuluri, A., Ukidve, A., Pan, D. C., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6579 · Cited by 414
“MHCII proteins are involved in antigen presentation to T cells to facilitate adaptive immunity (23).”
BackgroundCytokines in cancer immunity and immunotherapy
Smyth, M. J., Cretney, E., Kershaw, M. H., & Hayakawa, Y. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00199.x · Cited by 412
“IFN-a influences CD8þ T-cell and B-cell adaptive-immune responses (17, 18), by upregulating class I and class II MHC expression (19, 20), and increasing antigen presentation, immune surveillance, and cognate CD8þ T-cell-mediated killing of neoplastic cells (17, 19).”
BackgroundNLRC5: a key regulator of MHC class I-dependent immune responses
Kobayashi, K. S., & van den Elsen, P. J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3339 · Cited by 384
Muhlethaler-Mottet, A., Di Berardino, W., Otten, L. A., & Mach, B. (1998) · Immunity · doi:10.1016/s1074-7613(00)80468-9 · Cited by 377
Masternak, K., Muhlethaler-Mottet, A., Villard, J., Zufferey, M., Steimle, V., & Reith, W. (2000) · Genes & Development · doi:10.1101/gad.14.9.1156 · Cited by 355
“In contrast, CIITA is expressed in a complex and highly regulated pattern that governs all spatial, temporal, and quantitative aspects of MHC-II expression (Steimle et al. 1994; Mach et al. 1996; Boss 1997; Otten et al. 1998).”
BackgroundChang, C.-H., Guerder, S., Hong, S.-C., van Ewijk, W., & Flavell, R. A. (1996) · Immunity · doi:10.1016/s1074-7613(00)80681-0 · Cited by 350
“Thus,CIITA (Wake and Flavell, 1985; Steimle et al., 1993, 1994; Chang et al., 1994).”
BackgroundAnti-inflammatory and immunomodulatory effects of statins
Blanco-Colio, L. M., Tuñón, J., Martín-Ventura, J. L., & Egido, J. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00744.x · Cited by 347
Miller, D. M., Rahill, B. M., Boss, J. M., Lairmore, M. D., Durbin, J. E., Waldman, J. W., & Sedmak, D. D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.5.675 · Cited by 337
“CIITA, an IFNg–induced transcription factor, is required for activation of MHC class II promoters and transcription of class II genes (16).”
Steimle, V, Durand, B., Barras, E., Zufferey, M., Hadam, M. R., Mach, B., & Reith, W. (1995) · Genes & Development · doi:10.1101/gad.9.9.1021 · Cited by 338
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 321
The Primary Immunodeficiencies
Rosen, F. S., Cooper, M. D., & Wedgwood, R. J. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508173330707 · Cited by 324
Jain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., et al. (2021) · Blood · doi:10.1182/blood.2020007445 · Cited by 297
Tomazin, R., Boname, J., Hegde, N. R., Lewinsohn, D. M., Altschuler, Y., Jones, T. R., Cresswell, P., Nelson, J. A., Riddell, S. R., & Johnson, D. C. (1999) · Nature Medicine · doi:10.1038/12478 · Cited by 278
“To further characterize the effect of HCMV infection on class II, we constructed a cell line that constitutively expresses MHC class II by transfecting U373 cells with the class II transactivator gene CIITA (ref”
MethodMini‐review: Specificity and expression of CIITA, the master regulator of MHC class II genes
LeibundGut‐Landmann, S., Waldburger, J., Krawczyk, M., Otten, L. A., Suter, T., Fontana, A., Acha‐Orbea, H., & Reith, W. (2004) · European Journal of Immunology · doi:10.1002/eji.200424964 · Cited by 277
Masternak, K., Barras, E., Zufferey, M., Conrad, B., Corthals, G., Aebersold, R., Sanchez, J.-C., Hochstrasser, D. F., Mach, B., & Reith, W. (1998) · Nature Genetics · doi:10.1038/3081 · Cited by 276
HIV-1 Nef impairs MHC class II antigen presentation and surface expression
Stumptner-Cuvelette, P., Morchoisne, S., Dugast, M., Le Gall, S., Raposo, G., Schwartz, O., & Benaroch, P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221256498 · Cited by 274
Class II transactivator regulates the expression of multiple genes involved in antigen presentation.
Chang, C. H., & Flavell, R. A. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.2.765 · Cited by 267
“CIITA is also necessary and sufficient for the IFN-3,-inducible expression of class II genes (2, 3 ). The expression of CIITA itself is IFN-3, inducible, and its induction does not require de novo protein synthesis (2, 3). We have also demonstrated that the tyrosine kinase JAK1 is required for the transcription of the…”
BackgroundKanazawa, S., Okamoto, T., & Peterlin, B. M. (2000) · Immunity · doi:10.1016/s1074-7613(00)80159-4 · Cited by 262
Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: An Update
Dodiuk-Gad, R. P., Chung, W.-H., Valeyrie-Allanore, L., & Shear, N. H. (2015) · American Journal of Clinical Dermatology · doi:10.1007/s40257-015-0158-0 · Cited by 247
Hippo, Y., Yashiro, M., Ishii, M., Taniguchi, H., Tsutsumi, S., Hirakawa, K., Kodama, T., & Aburatani, H. (2001) · PubMed · Cited by 250
NLRC5 Limits the Activation of Inflammatory Pathways
Benko, S., Magalhaes, J. G., Philpott, D. J., & Girardin, S. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903900 · Cited by 235
RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency
Durand, B. (1997) · The EMBO Journal · doi:10.1093/emboj/16.5.1045 · Cited by 227
“CIITA is a differentially expressed gene that functionsof RFX5 and RFXAP in vitro does not generate a complex capable of binding specifically to the X box (data not as a molecular switch controlling cell-type specific and inducible MHC-II expression (Steimle et al., 1993, 1994;shown).”
BackgroundInterferon-α as an immunotherapeutic protein
Brassard, D. L., Grace, M. J., & Bordens, R. W. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.4.565 · Cited by 223
Fasolino, M., Schwartz, G. W., Patil, A. R., Mongia, A., Golson, M. L., Wang, Y. J., Morgan, A., Liu, C., Schug, J., Liu, J., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00531-x · Cited by 210
Class II Transactivator: Mastering the Art of Major Histocompatibility Complex Expression
Harton, J. A., & Ting, J. P.-Y. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.17.6185-6194.2000 · Cited by 217
“Human CIITA is encoded on chromosome 16 (119).”
BackgroundThe NLR gene family: from discovery to present day
Chou, W.-C., Jha, S., Linhoff, M. W., & Ting, J. P.-Y. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00849-x · Cited by 209
“CIITA shuttles between the nucleus and cytoplasm 32 , and its expression pattern precisely matches that of MHC II and its accessory proteins 33,34 .”
BackgroundThe NLR family of innate immune and cell death sensors
Sundaram, B., Tweedell, R. E., Prasanth Kumar, S., & Kanneganti, T.-D. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.012 · Cited by 209
Gobin, S. J. P., Peijnenburg, A., Keijsers, V., & van den Elsen, P. J. (1997) · Immunity · doi:10.1016/s1074-7613(00)80348-9 · Cited by 210
Genetic alterations and their clinical implications in DLBCL
Miao, Y., Medeiros, L. J., Li, Y., Li, J., & Young, K. H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0225-1 · Cited by 208
Induction of MHC Class I Expression by the MHC Class II Transactivator CIITA
Martin, B. K., Chin, K.-C., Olsen, J. C., Skinner, C. A., Dey, A., Ozato, K., & Ting, J. P.-Y. (1997) · Immunity · doi:10.1016/s1074-7613(00)80347-7 · Cited by 208
“…the classic MHC class II a and b chains (DR, DP, and DQ) (Steimle et al., 1993), Ii, and the DM proteins (Chang Major histocompatibility complex (MHC) class I–defi- et al., 1994; Chin et al., 1994; Steimle et al., 1994; Chang cient cell lines were used to demonstrate that theMHC and Flavell, 1995).”
MethodFortune, S. M., Solache, A., Jaeger, A., Hill, P. J., Belisle, J. T., Bloom, B. R., Rubin, E. J., & Ernst, J. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6272 · Cited by 206
“tuberculosis attenuates the response of infected macrophages to IFN- (7–10) in part by blocking the transcription of a subset of IFN- responsive genes including the type I receptor for the Fc domain of IgG (Fc RI or CD64) (11) and the MHC class II transactivator (CIITA),(3) which regulates MHC class II expression (12).”
BackgroundHaabeth, O. A. W., Tveita, A. A., Fauskanger, M., Schjesvold, F., Lorvik, K. B., Hofgaard, P. O., Omholt, H., Munthe, L. A., Dembic, Z., Corthay, A., et al. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00174 · Cited by 202
“However, in certain cells, MHC class II molecules may be induced by interferon gamma (IFN-γ) stimulation (63, 64).”
BackgroundZhu, X.-S., Linhoff, M. W., Li, G., Chin, K.-C., Maity, S. N., & Ting, J. P.-Y. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.6051-6061.2000 · Cited by 201
“CIITA is now shown to be required for IFN-g, interleukin-4 (IL-4), IL-10, IL-1, transforming growth factor b, and lipopolysaccharide control of class II genes (4, 5, 18, 32, 44).”
BackgroundThe Interferon-Gamma Paradox in Cancer
Zaidi, M. R. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0087 · Cited by 199
Regulation of transcription of MHC class II genes
Boss, J. M. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80166-5 · Cited by 195
T L ymphocyte –E ndothelial C ell I nteractions
Choi, J., Enis, D. R., Koh, K. P., Shiao, S. L., & Pober, J. S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104639 · Cited by 195
Immunogenomic Landscape of Hematological Malignancies
Dufva, O., Pölönen, P., Brück, O., Keränen, M. A. I., Klievink, J., Mehtonen, J., Huuhtanen, J., Kumar, A., Malani, D., Siitonen, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.002 · Cited by 190
Tompkins, S. M., Padilla, J., Dal Canto, M. C., Ting, J. P.-Y., Van Kaer, L., & Miller, S. D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.4173 · Cited by 190
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
Martin, A. M., Nirschl, T. R., Nirschl, C. J., Francica, B. J., Kochel, C. M., van Bokhoven, A., Meeker, A. K., Lucia, M. S., Anders, R. A., DeMarzo, A. M., et al. (2015) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2015.39 · Cited by 188
“To broadly simulate a T H 1-driven immune response, cells were cultured in the presence of IFN-γ for 48 hours; IFN-γ is a known mediator of PD-L1 expression in human cancer cell lines and has also been shown to induce MHC(1,23,26).”
Immunological aspects of microglia: relevance to Alzheimer's disease
Benveniste, E. N., Nguyen, V. T., & O'Keefe, G. M. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00045-6 · Cited by 187
Piskurich, J. F., Linhoff, M. W., Wang, Y., & Ting, J. P.-Y. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.431 · Cited by 187
“CIITA per se is induced by IFN-g treatment (4, 6, 52), and its expression is greatly reduced in STAT1 gene knockout mice (32) and decreased in IRF-1 gene knockout mice (18).”
BackgroundCIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter
Beresford, G. W., & Boss, J. M. (2001) · Nature Immunology · doi:10.1038/89810 · Cited by 185
Majumder, P., Gomez, J. A., Chadwick, B. P., & Boss, J. M. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071843 · Cited by 179
Kabacaoglu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 179
“Cluster of differentiation 40 (CD40) is a member of the tumor necrosis factor receptor superfamily and is expressed on APCs including monocyte subsets, DCs, macrophages, and B cells (190).”
BackgroundInfluentialCell Culture Models of Human Trophoblast II: Trophoblast Cell Lines—A Workshop Report
Shiverick, K. T., King, A., Frank, H.-G., Whitley, G. S. J., Cartwright, J. E., & Schneider, H. (2001) · Placenta · doi:10.1053/plac.2001.0647 · Cited by 179
Plasmacytoid dendritic cell in immunity and cancer
Mitchell, D., Chintala, S., & Dey, M. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.06.012 · Cited by 178
Riley, J. L., Westerheide, S. D., Price, J. A., Brown, J. A., & Boss, J. M. (1995) · Immunity · doi:10.1016/1074-7613(95)90033-0 · Cited by 177
Synergistic action of pro-inflammatory agents: cellular and molecular aspects
Paludan, S. R. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.1.18 · Cited by 177
Dendritic cell maturation in cancer
Moon, C. Y., Belabed, M., Park, M. D., Mattiuz, R., Puleston, D., & Merad, M. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00787-3 · Cited by 170
Sahiratmadja, E., Alisjahbana, B., de Boer, T., Adnan, I., Maya, A., Danusantoso, H., Nelwan, R. H. H., Marzuki, S., van der Meer, J. W. M., van Crevel, R., et al. (2007) · Infection and Immunity · doi:10.1128/iai.00602-06 · Cited by 174
“tuberculosis infection in macrophages can inhibit the induction of a subset of IFN- -responsive genes, including Fc receptor type I and major histocompatibility complex class II transactivator (12, 36, 46).”
BackgroundArmstrong, T. D., Clements, V. K., Martin, B. K., Ting, J. P.-Y., & Ostrand-Rosenberg, S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6886 · Cited by 174
Kretsovali, A., Agalioti, T., Spilianakis, C., Tzortzakaki, E., Merika, M., & Papamatheakis, J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.11.6777 · Cited by 167
“required for both IFN-g- and B-cell-specific expression of the class II genes (24, 40, 41).”
BackgroundHmama, Z., Gabathuler, R., Jefferies, W. A., de Jong, G., & Reiner, N. E. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4882 · Cited by 167
Muczynski, K. A., Ekle, D. M., Coder, D. M., & Anderson, S. K. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000061778.08085.9f · Cited by 166
Nagarajan, U. M., Louis-Plence, P., DeSandro, A., Nilsen, R., Bushey, A., & Boss, J. M. (1999) · Immunity · doi:10.1016/s1074-7613(00)80016-3 · Cited by 166
Landmann, S., Mühlethaler-Mottet, A., Bernasconi, L., Suter, T., Waldburger, J.-M., Masternak, K., Arrighi, J.-F., Hauser, C., Fontana, A., & Reith, W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.379 · Cited by 164
Herkel, J., Jagemann, B., Wiegard, C., Lazaro, J. F. G., Lueth, S., Kanzler, S., Blessing, M., Schmitt, E., & Lohse, A. W. (2003) · Hepatology · doi:10.1053/jhep.2003.50191 · Cited by 164
Mengos, A. E., Gastineau, D. A., & Gustafson, M. P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01147 · Cited by 160
“IL-1β and TGF-β directly down-regulate transcription of HLA-DR through CIITA and/or prevent IFN-γ induction of HLA-DR (16, 37, 38).”
BackgroundInfluentialNikodemova, M., Watters, J. J., Jackson, S. J., Yang, S. K., & Duncan, I. D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611907200 · Cited by 159
Silacci, P., Mühlethaler‐Mottet, A., Steimle, V., Reith, W., & Mach, B. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.4.1329 · Cited by 158
Pérarnau, B., Saron, M.-F., San Martin, B. R., Bervas, N., Ong, H., Soloski, M. J., Smith, A. G., Ure, J. M., Gairin, J. E., & Lemonnier, F. A. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199904)29:04<1243::aid-immu1243>3.0.co;2-a · Cited by 186
Zhou, H., & Glimcher, L. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90034-9 · Cited by 154
Paul, P., van den Hoorn, T., Jongsma, M. L. M., Bakker, M. J., Hengeveld, R. C. C., Janssen, L., Cresswell, P., Egan, D. A., van Ham, S. M., ten Brinke, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.023 · Cited by 160
Hu, J., Roy, S. K., Shapiro, P. S., Rodig, S. R., Reddy, S. P. M., Platanias, L. C., Schreiber, R. D., & Kalvakolanu, D. V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004885200 · Cited by 153
Spilianakis, C., Papamatheakis, J., & Kretsovali, A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.22.8489-8498.2000 · Cited by 154
Piskurich, J. F., Wang, Y., Linhoff, M. W., White, L. C., & Ting, J. P. ‐. (1998) · PubMed · Cited by 153
MHC class II-restricted antigen processing and presentation
Pieters, J. (2000) · Advances in immunology · doi:10.1016/s0065-2776(00)75004-8 · Cited by 171
Chin, K.-C., Mao, C. D., Skinner, C., Riley, J. L., Wright, K. L., Moreno, C. S., Stark, G. R., Boss, J. M., & Tingt, J. P.-Y. (1994) · Immunity · doi:10.1016/1074-7613(94)90039-6 · Cited by 150
Genetic structure characterization of Chileans reflects historical immigration patterns
Eyheramendy, S., Martínez, F. I., Manevy, F., Vial, C., & Repetto, G. M. (2015) · Nature Communications · doi:10.1038/ncomms7472 · Cited by 156
Fontes, J. D., Kanazawa, S., Jean, D., & Peterlin, B. M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.941 · Cited by 145
“The primers for PCR were as follows: GST-CBP(1-101), 59-CGCGGATCCATGGCTGAGAACTTGC and 59-GCAC TCGAGCTAGCCACCCAGGCCCTG; GST-CBP(461-661), 59-CGCGGATCC GGCACAGGGCAACAG and 59-GCACCGGAGCTATATCTTGTAGATTT TCTC; GST-CBP(1621-1891), 59- CGCGGATCCTGTATGCCACCATGG and 59-GCACTGGAGCTAGCCTCCCATCGCCTGC; and GST-CBP(2058-2163), 59-…”
MethodInfluentialNitric Oxide Attenuates Vascular Smooth Muscle Cell Activation by Interferon-γ
Shin, W. S., Hong, Y.-H., Peng, H.-B., De Caterina, R., Libby, P., & Liao, J. K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.19.11317 · Cited by 146
Briere, D. M., Sudhakar, N., Woods, D. M., Hallin, J. F., Engstrom, L. D., Aranda, R., Chiang, H., Sodré, A. L., Olson, P., Weber, J. S., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2091-y · Cited by 158
Genome-wide analysis of PPARα activation in murine small intestine
Bünger, M., van den Bosch, H. M., van der Meijde, J., Kersten, S., Hooiveld, G. J. E. J., & Müller, M. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00198.2006 · Cited by 144
“The downregulated genes of the merged network all linked to MYC, caspase 3 (CASP3), major histocompatibility class (MHC) 2 transactivator (MHC2TA), epidermal growth factor receptor (EGFR), or lymphocyte-specific protein tyrosine kinase (LCK), which themselves were also PPAR -dependently downregulated.”
BackgroundInfluentialHervier, B., Béziat, V., Haroche, J., Mathian, A., Lebon, P., Ghillani‐Dalbin, P., Musset, L., Debré, P., Amoura, Z., & Vieillard, V. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30313 · Cited by 157
“This cytokine is believed to promote Th1 cell polarization (42) and to facilitate specific cytotoxicity by overexpression of class I and class II MHC molecules (43), as well as to facilitate antigen processing (44) and immunoglobulin switching (45).”
BackgroundDysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy
Han, J., Wu, M., & Liu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190333 · Cited by 169
Modulation of Major Histocompatibility Class II Protein Expression by Varicella-Zoster Virus
Abendroth, A., Slobedman, B., Lee, E., Mellins, E., Wallace, M., & Arvin, A. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1900-1907.2000 · Cited by 139
TRANSCRIPTIONAL REGULATION DURING B CELL DEVELOPMENT
Henderson, A., & Calame, K. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.163 · Cited by 137
Scholl, T., Mahanta, S. K., & Strominger, J. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6330 · Cited by 137
Piskurich, J. F., Wang, Y., Linhoff, M. W., White, L. C., & Ting, J. P.-Y. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.1.233 · Cited by 136
Cell Culture Models of Trophoblast II: Trophoblast Cell Lines— A Workshop Report
King, A., Thomas, L., & Bischof, P. (2000) · Placenta · doi:10.1053/plac.1999.0526 · Cited by 135
Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity
Raj, P., Rai, E., Song, R., Khan, S., Wakeland, B. E., Viswanathan, K., Arana, C., Liang, C., Zhang, B., Dozmorov, I., et al. (2016) · eLife · doi:10.7554/elife.12089 · Cited by 133
“Expression levels are tightly controlled by a variety of transcription factors unique to these cell lineages and their expression impacts a variety of functional processes in the immune system (Cresswell, 1994; Krawczyk et al., 2004; Steimle et al., 1994; Reith et al., 2005).”
BackgroundKuppner, M. C., Gastpar, R., Gelwer, S., Nössner, E., Ochmann, O., Scharner, A., & Issels, R. D. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200105)31:5<1602::aid-immu1602>3.0.co;2-w · Cited by 213
Metadata
- Authors
- Steimle, V., Siegrist, C.-A., Mottet, A., Lisowska-Grospierre, B., & Mach, B.
- Affiliations
- University of Geneva (CH)
- Jeantet Laboratory of Molecular Genetics, Department of Genetics and Microbiology, University of Geneva Medical School, CH-1211 Geneva 4, Switzerland.
- INSERM U132, Hôpital des Enfants Malades, 15015 Paris, France.
- Venue
- Science
- Published
- 1994-07
- Volume
- 265
- Issue
- 5168
- Pages
- 106-109
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2060320549
- Cited by
- 898
- References
- 29
- Citations by year
- 2026: 33 · 2025: 35 · 2024: 39 · 2023: 49 · 2022: 35 · 2021: 32 · 2020: 25 · 2019: 20 · 2018: 22 · 2017: 19 · 2016: 27 · 2015: 21 · 2014: 18 · 2013: 13 · 2012: 29
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- MHC class II expression, interferon-gamma, CIITA, MHC class II deficiency, gene expression regulation, transcriptional activation
- MeSH terms
- Histocompatibility Antigens Class II, Cell Line, Chromosome Mapping, Chromosomes, Human, Pair 16, Fibroblasts, Gene Expression Regulation, Genes, MHC Class II, Humans, Interferon-gamma, Models, Genetic, Nuclear Proteins, RNA, Messenger, Transfection, Tumor Cells, Cultured, Trans-Activators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.